Apply to trial NCT07002320

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    They see only the answers needed to decide if you can be screened.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

We save your progress under this email so you can come back later, and the study team uses it to reach you.

By clicking Start, you agree to our terms of service.